Skip to main content
    E

    enGene Therapeutics Inc. (ENGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.72
    -0.17 (-8.99%)

    Market Cap: $161.51M

    Last updated: Nov 17, 2026 at 4:33 PM ET

    enGene Therapeutics Inc. (ENGN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    enGene Therapeutics (ENGN) has a market cap of $161.51M and an enterprise value of $145.84M. Its share count is up 36.47% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 9.70% below the market cap, as cash exceeds debt.

    Market Cap$161.51M
    Enterprise Value$145.84M
    Latest price (Nov 17, 2026)$1.72

    Key Dates

    The next earnings report is expected on Dec 22, 2026, covering the quarter ending Oct 31, 2026.

    Next Earnings DateDec 22, 2026 (expected)
    Last Earnings DateSep 8, 2026
    Fiscal Year EndOctober

    Share Statistics

    The share count rose 0.01% in the quarter ended Jul 31, 2026 and grew 25.65% a year over 2 years.

    Shares Outstanding69.73M
    Shares Change (YoY)+36.47%
    Shares Change (QoQ)+0.01%
    Share Count Growth (2Y CAGR)+25.65%

    Valuation Ratios

    Forward P/S34.5x
    P/B Ratio0.5x

    Price Statistics

    The stock is down 79.84% over 52 weeks and trades 3.91% below its 50-day average.

    Beta (1Y)2.13
    52-Week Change-79.84%
    1-Month Change+8.86%
    3-Month Change-7.03%
    6-Month Change+12.42%
    Total Return (1Y)-79.84%
    Total Return (3Y CAGR)-39.19%
    Return vs SPY (1Y)-86.56%
    Max Drawdown (1Y)-88.17%
    Max Drawdown (3Y)-92.11%
    Sharpe Ratio (1Y)-0.77
    Correlation with SPY (1Y)0.16
    50-Day Average$1.79
    200-Day Average$3.87
    52-Week Range$1.40 to $12.25
    RSI (14 Days)48.1
    Average Volume (20 Days)1.75M

    Price chart

    Financial Position

    Current assets cover 10.21x current liabilities, and total debt is 0.11x shareholder equity.

    Current Ratio10.21x
    Quick Ratio10.21x
    Debt / Equity0.11x
    Interest Coverage-38.34x

    Returns and Efficiency

    Return on invested capital is -42.15% and return on equity is -56.61% over the last 12 months.

    Return on Equity (ROE)-56.61%
    Return on Assets (ROA)-45.21%
    Return on Invested Capital (ROIC)-42.15%
    ROE (5Y Average)-53.12%
    ROA (5Y Average)-44.39%

    Scores

    ENGN has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$171.00K
    Operating Income-$136.65M
    Pretax Income-$130.86M
    Net Income-$130.36M
    Reported EPS (TTM)-$1.13

    Trailing 12 months through Jul 31, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 79.87% of the $288.32M in total assets.

    Cash and Equivalents$41.02M
    Total Debt$25.35M
    Net Cash$15.67M
    Net Cash Per Share$0.22
    Working Capital$250.69M
    Shareholder Equity$230.29M
    Book Value Per Share$3.30
    Total Assets$288.32M
    Total Liabilities$58.03M

    Balance sheet as of Jul 31, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$103.31M
    FCF Per Share-$1.55
    Depreciation and Amortization$2.08M

    Trailing 12 months through Jul 31, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+18.81%
    Tangible Book Per Share Growth (2Y CAGR)+18.81%

    Revenue and profit by year

    Dividends and Yields

    ENGN does not pay a dividend.

    Buyback Yield-11.51%
    Shareholder Yield-11.51%

    Peer Position

    Against 4 similar companies, ENGN has the 3rd highest ROIC.

    ROIC-42.15% vs -68.60% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -64.32% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ENGN

    What is ENGN's market cap?

    enGene Therapeutics has a market cap of $161.51M. Its enterprise value, which adds debt and subtracts cash, is $145.84M.

    How many shares of ENGN are outstanding?

    enGene Therapeutics has 69.73M shares outstanding. The count is up 36.47% from a year earlier.

    Does ENGN pay a dividend?

    No. enGene Therapeutics does not pay a dividend.

    How much debt does ENGN have?

    enGene Therapeutics has $25.35M of total debt and $41.02M of cash and equivalents, a net cash position of $15.67M.